Results 201 to 210 of about 28,228 (226)

Phase quantification of antihypertensive drugs – Chlorthalidone, Hydrochlorothiazide, Losartan and combinations, Losartan/Chlorthalidone and Losartan/Hydrochlorothiazide – by the Rietveld method

Journal of Pharmaceutical and Biomedical Analysis, 2014
The identification and quantification of crystalline phases of antihypertensive drugs - Losartan potassium (LOS-K), Hydrochlorothiazide (HCTZ) and Chlorthalidone (CTD) were carried out by means of X-ray powder diffraction data and the Rietveld method.
Weberton R. do Carmo, Renata Diniz, Fabio Furlan Ferreira   +2 more
openaire   +3 more sources

Pharmacokinetic evaluation of losartan

Expert Opinion on Drug Metabolism & Toxicology, 2011
Blockade of the renin-angiotensin system is one of the major therapeutic strategies in the management of patients with essential hypertension, congestive heart failure and diabetic as well as non-diabetic renal diseases. As the first angiotensin II receptor blocker (ARB) on the market, losartan belongs to the most frequently prescribed ARB.The present ...
Michel Burnier, Grégoire Wuerzner
openaire   +3 more sources

Losartan in Cardiovascular Disease

Future Cardiology, 2005
Hypertension is a major risk factor for the development of cardiovascular disease. Numerous placebo-controlled trials have demonstrated that treatment of hypertension results in substantial reduction of hypertension-related vascular events. The benefit of specific therapies beyond their effect on blood pressure is well established.
Vasilios Papademetriou, Ewout J. Hoorn, Sanne de Vogel   +2 more
openaire   +3 more sources

Losartan-Induced Angioedema

Annals of Pharmacotherapy, 1999
OBJECTIVE: To report a case of angioedema associated with losartan administration. CASE SUMMARY: A 45-year-old white man with a history of hypertension and gout was treated with losartan/hydrochlorothiazide, allopurinol, and colchicine. The patient experienced two episodes of angioedema within a 10-hour period.
openaire   +3 more sources

Losartan induced fetal toxicity

The Indian Journal of Pediatrics, 2003
Losartan is a specific angiotensin II receptor antagonist. Although the teratogenic effects of angiotensin converting enzyme (ACE) inhibitors are well documented there are limited reports of losartan induced fetal toxicity. The authors report a case of incomplete ossification of skull bones, transient oliguria and feed intolerance in a newborn ...
Ashwani Singhal, Bonilla Nayar, Rajiv Aggarwal, Neena Malhotra   +3 more
openaire   +3 more sources

The pharmacokinetics of losartan in renal insufficiency

Journal of Hypertension, 1995
To determine the effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of losartan (MK-954) and its metabolite E3174.A two-center, unblinded trial was performed in 18 patients (age range 31-63 years) with various degrees of renal function grouped according to the renal clearance of creatinine: group I, creatinine clearance > or ...
Shahnaz Shahinfar, Domenic A. Sica, C. I. Furtek, M.-W. Lo, C. E. Halstenson, William F. Keane, Wayne Shaw, Michael Ritter, K. Lipschutz, T. W. B. Gehr   +9 more
openaire   +3 more sources

Treatment of posttransplant erythrocytosis with losartan

Transplantation Proceedings, 1997
POSTTRANSPLANT erythrosis (PTE) develops in 9% to 22% of renal transplant recipients.1–3 Defined as a persistently increased hematocrit (>0.51), it occures most commonly during the first 2 years posttransplant in hypertensive males with excellent allograft function.4 After reports of anemia in renal transplant recipients undergoing ACE inhibitor ...
V. Fournier, C. Bresson-Vautrin, Didier Ducloux, J. M. Chalopin   +3 more
openaire   +3 more sources

Losartan-Induced Hepatotoxicity

JAMA: The Journal of the American Medical Association, 1997
To the Editor. —Losartan is an orally active, nonpeptide angiotensin II type I receptor antagonist that has been licensed for the treatment of hypertension in many countries. This new drug also produces beneficial hemodynamic effects both acutely and with long-term dosing in patients with symptomatic heart failure. 1 Adverse events related to losartan
openaire   +2 more sources

Hyperuricemia and Gout: The Role of Losartan

The Senior Care Pharmacist, 2023
Losartan is the only angiotensin II receptor blocker that has shown to significantly lower uric acid levels. The addition of or switch to losartan as an antihypertensive agent for patients with gout is recommended by clinical guidelines because of its benefit as a uricosuric agent.
openaire   +2 more sources

Losartan-Induced Hepatic Injury

Journal of Clinical Gastroenterology, 2002
Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug has demonstrated that it is safe. Losartan-induced hepatic toxicity is extremely rare. We report a case of severe hepatic toxicity and fibrosis caused by losartan use, and we review four previously reported cases.
Gulsen Ozbay, Resat Ozaras, Fehmi Tabak, Yildirim Aktuglu, Mithat Biyikli, Ali Mert, Hakan Senturk, Recep Öztürk   +7 more
openaire   +3 more sources